



# Vivek Surana & Associates

Practicing Company Secretaries

Annexure IV

Format of the confirmation to be submitted by the Statutory Auditors/ Practicing Chartered Accountant/ Practicing Company Secretary on their letterhead:

The Chief General Manager  
Listing Operation,  
BSE Limited,  
20<sup>th</sup> Floor, P. J. Towers  
Dalal Street,  
Mumbai – 400001.

Dear Sir,

**Sub: Application for “In-principle approval” prior to issue and allotment of 12,56,250 Convertible warrants on preferential basis under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

We, Vivek Surana & Associates, Practicing Company Secretaries have verified the relevant records and documents of Concord Drugs Limited with respect to the proposed preferential issue by the company as per Chapter V of SEBI (ICDR) Regulations, 2018 and certify that:

- a) None of the proposed allottee(s) has/ have sold any equity shares of the company during the 90 trading days preceding the relevant date. Further, where the proposed allottee(s) is/ are promoter/ promoter group entity, then none of entities in the promoter and promoter group entities has/ have sold any equity share of the company during the 90 trading days preceding the relevant date.
- b) The pre-preferential shareholding of each of proposed allottee(s) has been locked in accordance with Regulation 167 (6) SEBI (ICDR) Regulations, 2018. Further, there is no sale/ pledge of pre-preferential holding from (30.08.2022) till 07.09.2022. The details of allottee-wise pre-preferential shareholding and lock-in thereon is as given hereunder:

| Name of the Proposed Allottee | DP ID *          | Qty       | Lock-in details |            |
|-------------------------------|------------------|-----------|-----------------|------------|
|                               |                  |           | From            | To         |
| Mr. S. Nagi Reddy             | 1302340000387612 | 2,90,000  | 30.08.2022      | 30.09.2024 |
| Mr. S. Nagi Reddy             | 1302340000387612 | 13,13,000 | 30.08.2022      | 31.12.2023 |
| Mr. S. Nagi Reddy             | 1205140000385981 | 6,81,399  | 30.08.2022      | 31.12.2023 |
| Mr. S. Manoj Kumar Reddy      | 1302340000388105 | 2,14,000  | 30.08.2022      | 30.09.2024 |
| Mr. S. Manoj Kumar Reddy      | 1302340000388105 | 4,51,000  | 30.08.2022      | 31.12.2023 |
| Mr. S. Manoj Kumar Reddy      | 1205140000450797 | 3,35,000  | 30.08.2022      | 31.12.2023 |

(\*) client id/ folio no in case allottee hold the securities in physical form

Plot No. 8-2-603/23/3, 2nd Floor, Banjara Hills, Road No. 10, Hyderabad-500034, Telangana  
Ph: +91 9959581348, Email: viveksurana24@gmail.com





## Vivek Surana & Associates

Practicing Company Secretaries

- c) None of the proposed allottees belonging to promoter(s) or the promoter group is ineligible for allotment in terms of Regulations 159 of SEBI (ICDR) Regulations, 2018.
- d) The proposed issue is being made in accordance with the requirements of Chapter V of SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018, Section 42 and 62 of the Companies Act 2013 and Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014 and other requirements of Companies Act, 2013. Further, the company has complied with all legal and statutory formalities and no statutory authority has restrained the company from issuing these proposed securities.
- e) The proposed preferential issue is being made in compliance with the provisions of Memorandum of Association (MoA) and Article of Association (AoA) of the company. It is further confirmed that for the proposed preferential issue, the price of the equity shares of the company has been determined in compliance with the valuation requirement as mentioned in the AoA of the company."
- f) The total allotment to the allottee or allottees acting in concert in the present preferential issue or in the same financial year i.e., 2022-23 is more than 5% of the post issue fully diluted share capital of the issuer.

OR

~~The total allotment to the allottee or allottees acting in concert in the present preferential issue or in the same financial year i.e., 2022-23 is less than 5% of the post issue fully diluted share capital of the issuer.~~

For Vivek Surana & Associates



Vivek Surana

Membership No. A24531, CP No 12901

UDIN: A024531D000937861

Date: 07.09.2022